Combined anti-proliferative and anti-angiogenic strategies for cancer.
BACKGROUND
In recent years, anti-angiogenic treatments have been shown to synergize with traditional chemotherapeutic and radiotherapeutic regimens. Combining anti-angiogenesis with targeted anti-proliferative agents might also be synergistic. Several lines of evidence point to the validity of this approach, and preliminary results of ongoing and recent studies support it.


OBJECTIVE
The background and current status of anti-angiogenic and anti-proliferative treatments will be summarized, as well as the evidence supporting and antagonizing their combined use in the clinic.


METHODS
Relevant literature was reviewed using PubMed search, and recent major conference proceedings and other relevant data were searched through internet publications.


CONCLUSIONS
Combining anti-angiogenic and anti-proliferative treatments seems a promising approach, although not in all clinical circumstances.
Bar
Jair
J
Chaim Sheba Medical Center, Division of Oncology, 52621 Tel Hashomer, Israel. bar.jair@gmail.com
Onn
Amir
A
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D049109:Cell Proliferation / Q000187:drug effects*; D018849:Controlled Clinical Trials as Topic; D016503:Drug Delivery Systems; D004357:Drug Synergism; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents